

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul83lec

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:36:59 ON 15 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 15:38:40 ON 15 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 NOV 2006 HIGHEST RN 913238-98-9

DICTIONARY FILE UPDATES: 14 NOV 2006 HIGHEST RN 913238-98-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading c:\program files\stnexp\queries\10.541615.str.A

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:39:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS
SEARCH TIME: 00.00.01

11 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:39:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 208 TO ITERATE

100.0% PROCESSED 208 ITERATIONS
SEARCH TIME: 00.00.01


182 ANSWERS

L3 182 SEA SSS FUL L1

=> d scan

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[2-(dimethylamino)ethoxy]phenyl]-, (1S)-(9CI)
MF C25 H31 N O6 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C56 H59 N O8 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI)
 MF C21 H20 Cl F O5 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(2-hydroxyethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI)
 MF C51 H50 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(difluoromethoxy)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI)
 MF C22 H21 Cl F2 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-2-β-D-glucopyranosylphenoxy]-, methyl ester (9CI)
 MF C24 H26 O8 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucopyranose, 1-C-[3-[(5-ethylbenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI)
 MF C55 H52 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-methoxyphenyl]-, (1S)- (9CI)
 MF C22 H23 Cl O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-hydroxyphenyl]-
 2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI)
 MF C49 H46 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 182 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI)
 MF C22 H23 Cl O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

168.70

169.33

FILE 'CAPLUS' ENTERED AT 15:41:23 ON 15 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Nov 2006 VOL 145 ISS 21

FILE LAST UPDATED: 14 Nov 2006 (20061114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 4 L3

=> d l4 ed ibib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 03 Feb 2006

ACCESSION NUMBER: 2006:103511 CAPLUS

DOCUMENT NUMBER: 144:171191

TITLE: Preparation of 1-(1-naphthyl)-1,5-anhydroglucitol derivatives, prodrugs thereof and salts thereof, and therapeutic agents containing them for diabetes

INVENTOR(S): Matsuoka, Hiroharu; Sato, Tsutomu; Nishimoto, Masahiro; Kato, Yasuharu; Sakaitani, Masahiro; Lee, Sang-Hak

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006011502	A1	20060202	WO 2005-JP13716	20050727
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,			

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

JP 2004-218895

A 20040727


JP 2004-343942

A 20041129

OTHER SOURCE(S):

MARPAT 144:171191

GI



I

AB The title compds. (I) [wherein m = an integer of 1-3; R1-R4 = H, CORx, each (un)substituted C1-6 alkyl or C7-14 aralkyl; Rx = each (un)substituted C1-6 alkyl, aryl, heteroaryl, C1-6 alkoxy, or NH₂; Ar1 = (un)substituted naphthyl; A = (un)substituted heteroaryl optionally fused to aromatic hydrocarbon or aromatic heterocyclic ring], prodrugs thereof, or pharmaceutically acceptable salts of either are prepared. These compds. have the function of reducing a blood sugar level and have preferable properties required of medicines, such as long-lasting drug activity and are useful in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes) and insulin-independent diabetes (type II diabetes), complications of diabetes, and obesity. Thus, a solution of 0.81 g 2-[(4-bromonaphthalen-2-yl)methyl]benzo[b]thiophene in 15 mL dry THF was treated dropwise with BuLi/hexane (1.6 M, 1.58 mL) at -78° over 5 min, stirred at -78° for 5 min, treated dropwise with a solution of 1.36 g (3R,4S,5R,6R)-3,4,5-Tris-benzyloxy-6-benzyloxymethyltetrahydropyran-2-one in 10 mL dry THF at -78°, stirred at -78° for 2 h to give, after workup and silica gel flash chromatog., 75% (3R,4S,5S,6R)-2-[3-(Benzo[b]thiophen-2-ylmethyl)naphthalen-1-yl]-3,4,5-trisbenzyloxy-6-benzyloxymethyltetrahydropyran-2-ol (II). A solution of 1.4 g II in CH₂Cl₂ was treated dropwise with 0.34 mL triethylsilane and 0.24 mL BF₃.OEt₂ at 0° and stirred at room temperature for 2 h to give, after workup and silica gel chromatog., 80.2% (2S,3R,4R,5S,6R)-2-[3-(Benzo[b]thiophen-2-ylmethyl)naphthalen-1-yl]-3,4,5-trisbenzyloxy-6-benzyloxymethyltetrahydropyran (III). A solution of 1.1 g III in 30 mL CH₂Cl₂ was treated dropwise with 3.5 mL di-Me sulfide and 1.75 mL BF₃.OEt₂ at 0° and stirred at room temperature for 3 days to give, after workup and silica gel flash chromatog., 58.2% (2S,3R,4R,5S,6R)-2-[3-(Benzo[b]thiophen-2-ylmethyl)naphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol (IV). IV in vitro human Na⁺-glucose transporter (SGLT2, sodium-dependent glucose transporter 2) with IC₅₀ of 18 nM.

IT 874357-13-8P, (3R,4S,5R,6R)-2-[3-[(Benzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]-3,4,5-tris(benzyloxy)-6-[(benzyloxy)methyl]tetrahydropyran-2-ol 874357-14-9P


874357-20-7P, (3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-2-[3-[(5-fluorobenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran-2-ol 874357-21-8P, (2S,3S,4R,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-2-[3-[(5-fluorobenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran 874357-24-1P, (3R,4S,5R,6R)-2-[3-[(Benzo[b]thiophen-2-yl)methyl]-4-methoxynaphthalen-1-yl]-3,4,5-tris(benzyloxy)-6-[(benzyloxy)methyl]tetrahydropyran-2-ol 874357-25-2P, (2S,3S,4R,5R,6R)-2-[3-[(Benzo[b]thiophen-2-yl)methyl]-4-methoxynaphthalen-1-yl]-3,4,5-tris(benzyloxy)-6-[(benzyloxy)methyl]tetrahydropyran 874357-28-5P, (2R,3R,4S,5R)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-[3-[(5-methoxybenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran-6-ol 874357-30-9P, (2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-[3-[(5-methoxybenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran 874357-34-3P, (3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)-2-[3-[(5-ethylbenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran-2-ol 874357-35-4P, (2R,3R,4R,5S,6S)-3,4,5-Tris(benzyloxy)-2-(benzyloxymethyl)-6-[3-[(5-ethylbenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1-(1-naphthyl)-1,5-anhydroglucitol derivs. as sodium-dependent glucose transporter inhibitors and hypoglycemics)

RN 874357-13-8 CAPLUS

CN D-Glucopyranose, 1-C-[3-(benzo[b]thien-2-ylmethyl)-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


* Absolute stereochemistry.



RN 874357-14-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-20-7 CAPLUS

CN D-Glucopyranose, 1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-21-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-24-1 CAPLUS

CN D-Glucopyranose, 1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxy-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-25-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxy-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-28-5 CAPLUS

CN D-Glucopyranose, 1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-30-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-34-3 CAPLUS

CN D-Glucopyranose, 1-C-[3-[(5-ethylbenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874357-35-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-ethylbenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.




IT 842132-74-5P, (2S,3R,4R,5S,6R)-2-[3-[(Benzo[b]thiophen-2-yl)methyl]-4-methoxynaphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol 874357-09-2P, (2S,3R,4R,5S,6R)-2-[3-[(Benzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol 874357-15-0P, (2S,3R,4R,5S,6R)-2-[3-[(5-Fluorobenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol 874357-26-3P, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[3-[(5-methoxybenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran-3,4,5-triol 874357-31-0P, (2S,3R,4R,5S,6R)-2-[3-[(5-Ethylbenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol 874357-36-5P, (2S,3R,4R,5S,6R)-2-[3-[(5-Chlorobenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]-6-hydroxymethyltetrahydropyran-3,4,5-triol 874357-37-6P, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[3-[(5-methylbenzo[b]thiophen-2-yl)methyl]naphthalen-1-yl]tetrahydropyran-3,4,5-triol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(1-naphthyl)-1,5-anhydroglucitol derivs. as sodium-dependent glucose transporter inhibitors and hypoglycemics)

RN 842132-74-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxy-1-naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-09-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-1-naphthalenyl]-
, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-15-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-26-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874357-31-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-ethylbenzo[b]thien-2-yl)methyl]-1-

naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-36-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chlorobenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874357-37-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methylbenzo[b]thien-2-yl)methyl]-1-naphthalenyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

39

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 21 Oct 2005

ACCESSION NUMBER: 2005:1132895 CAPLUS

DOCUMENT NUMBER: 143:387313

TITLE: Preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependent transporter

INVENTOR(S): Nomura, Sumihiro; Kawanishi, Eiji; Ueta, Kiichiro

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: U.S. Pat. Appl. Publ., 123 pp., Cont.-in-part of Appl. No. PCT/JP04/011312.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005233988	A1	20051020	US 2005-45446	20050131
WO 2005012326	A1	20050210	WO 2004-JP11312	20040730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2006080577	A1	20060803	WO 2006-JP301921	20060131
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006217323	A1	20060928	US 2006-446014	20060602
US 2006229260	A1	20061012	US 2006-453728	20060615
US 2006234954	A1	20061019	US 2006-453727	20060615
PRIORITY APPLN. INFO.:			US 2003-491534P	P 20030801
			WO 2004-JP11312	A2 20040730
			US 2003-491523P	P 20030801
			US 2003-519209P	P 20031112
			US 2003-519210P	P 20031112
			US 2003-519381P	P 20031112
			US 2004-579722P	P 20040615
			US 2004-579730P	P 20040615
			US 2004-579792P	P 20040615
			US 2004-903034	A3 20040730
			US 2004-903136	A3 20040730
			US 2004-903234	A3 20040730
			JP 2005-23728	A 20050131
			US 2005-45446	A 20050131
			US 2005-726653P	P 20051017

OTHER SOURCE(S): MARPAT 143:387313

GI



AB Glycosides I, wherein A and B are: (1) A is unsatd. monocyclic heterocyclic, and B is unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene, (2) A is benzene, and B is unsatd. monocyclic heterocyclic or unsatd. fused hetero-bicyclic, or (3) A is unsatd. fused hetero-bicyclic, and B are independently unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene; X is a carbon atom or a nitrogen atom; Y is $-(CH_2)_n-$ (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyper-insulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. The pharmaceutical compns. may be orally administered to mammalian species including human beings, apes, dogs, etc., for example, in the dosage form of tablet, capsule, granule or powder, or administered in the form of injection preparation, or intra-nasally, or in the form of transdermal patch. Thus, 1-(β -D-glucopyranosyl)-4-chloro-3-(6-ethyl-benzo[b]thiophen-2-yl-methyl)benzene was prepared as antidiabetic agent and having inhibitory activity against sodium-dependent transporter.

IT 761423-35-2P 761423-36-3P 761423-38-5P
 761423-80-7P 761423-81-8P 761423-83-0P
 761423-86-3P 761423-87-4P 761424-02-6P
 842132-72-3P 842132-73-4P 842132-74-5P
 842132-75-6P 842132-76-7P 842132-77-8P
 842132-78-9P 842132-79-0P 842132-80-3P
 842132-81-4P 842132-82-5P 842132-83-6P
 842132-84-7P 842132-85-8P 842132-86-9P
 842132-87-0P 842132-88-1P 842132-89-2P
 842132-90-5P 842132-91-6P 842132-92-7P
 842132-93-8P 842132-94-9P 842132-95-0P
 842132-96-1P 842132-97-2P 842132-98-3P
 842132-99-4P 842133-00-0P 842133-55-5P
 842133-56-6P 842134-45-6P 842134-54-7P
 842134-55-8P 842134-83-2P 842134-98-9P
 842134-99-0P 842136-98-5P 866605-86-9P
 866606-34-0P 866606-35-1P 866606-36-2P
 866606-37-3P 866606-39-5P 866606-41-9P
 866606-44-2P 866607-32-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)

RN 761423-35-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-36-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-38-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(3-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-80-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-fluorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-81-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-83-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxyphenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-86-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-87-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-02-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-72-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-73-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-ethoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-74-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxy-1-naphthalenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-75-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(trifluoromethyl)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-76-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-methylphenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-77-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-methylphenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-78-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-79-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-80-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-81-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5,7-dimethylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-82-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-83-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-84-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-85-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(trifluoromethyl)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-86-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-87-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-fluoro-3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-88-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-chlorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-89-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-90-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-91-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-92-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-fluoro-6-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-93-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-94-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-95-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-96-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-fluoro-3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-97-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chlorobenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-98-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-99-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-ethylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-00-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-(trifluoromethyl)phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-55-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1-oxidobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-56-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1,1-dioxidobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-45-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-ethylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-54-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-propoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-55-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(2-fluoroethoxy)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-83-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-ethoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-98-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(difluoromethoxy)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-99-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[6-(difluoromethoxy)benzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842136-98-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-ethoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866605-86-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(1-methylethoxy)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-34-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(6-ethoxybenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-35-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-36-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[6-(2,2-difluoroethoxy)benzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-37-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-ethoxybenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-39-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[5-(2-fluoroethoxy)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-41-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[6-(2-fluoroethoxy)benzo[b]thien-2-yl]methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866606-44-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(6-methoxybenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866607-32-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-ethylbenzo[b]thien-2-yl)methyl]phenyl]-, tetraacetate, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 761422-37-1P 842132-54-1P 842133-53-3P
842133-54-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)

RN 761422-37-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-54-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylhydroxymethyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-53-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-, tetraacetate, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-54-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1-oxidobenzo[b]thien-2-yl)methyl]phenyl]-, tetraacetate, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 11 Feb 2005

ACCESSION NUMBER: 2005:120950 CAPLUS

DOCUMENT NUMBER: 142:219491

TITLE: Preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter

INVENTOR(S): Nomura, Sumihiro; Kawanishi, Eiji; Ueta, Kiichiro

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan


SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012326	A1	20050210	WO 2004-JP11312	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260761	A1	20050210	AU 2004-260761	20040730
CA 2534024	AA	20050210	CA 2004-2534024	20040730
EP 1651658	A1	20060503	EP 2004-771314	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1829729	A	20060906	CN 2004-80022007	20040730
BR 2004013232	A	20061003	BR 2004-13232	20040730
US 2005233988	A1	20051020	US 2005-45446	20050131
NO 2006000220	A	20060502	NO 2006-220	20060116
US 2006217323	A1	20060928	US 2006-446014	20060602
US 2006229260	A1	20061012	US 2006-453728	20060615
US 2006234954	A1	20061019	US 2006-453727	20060615
PRIORITY APPLN. INFO.:			US 2003-491534P	P 20030801
			US 2003-491523P	P 20030801
			US 2003-519209P	P 20031112
			US 2003-519210P	P 20031112
			US 2003-519381P	P 20031112
			US 2004-579722P	P 20040615
			US 2004-579730P	P 20040615
			US 2004-579792P	P 20040615
			US 2004-903034	A3 20040730
			US 2004-903136	A3 20040730
			US 2004-903234	A3 20040730
			WO 2004-JP11312	W 20040730
OTHER SOURCE(S):			MARPAT 142:219491	
GI				



AB Glycosides I, wherein A and B are: (1) A is unsatd. monocyclic heterocyclic, and B is unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene, (2) A is benzene, and B is unsatd. monocyclic heterocyclic or unsatd. fused hetero-bicyclic, or (3) A is unsatd. fused hetero-bicyclic, and B are independently unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene; X is a carbon atom or a

nitrogen atom; Y is $-(CH_2)_n-$ (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyper-insulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. The pharmaceutical compns. may be orally administered to mammalian species including human beings, apes, dogs, etc., for example, in the dosage form of tablet, capsule, granule or powder, or parenterally administered in the form of injection preparation, or intra-nasally, or in the form of tranucleosideermal patch. Thus, 1-(β -D-glucopyranosyl)-4-chloro-3-(6-ethylbenzo[b]thiophen-2-yl-methyl)benzene was prepared as antidiabetic agent and having inhibitory activity against sodium-dependent transporter.

IT 761423-35-2P 761423-36-3P 761423-38-5P
 761423-80-7P 761423-81-8P 761423-83-0P
 761423-86-3P 761423-87-4P 842132-57-4P
 842132-72-3P 842132-73-4P 842132-74-5P
 842132-75-6P 842132-76-7P 842132-77-8P
 842132-78-9P 842132-79-0P 842132-80-3P
 842132-81-4P 842132-82-5P 842132-83-6P
 842132-84-7P 842132-85-8P 842132-86-9P
 842132-87-0P 842132-88-1P 842132-89-2P
 842132-90-5P 842132-91-6P 842132-92-7P
 842132-93-8P 842132-94-9P 842132-95-0P
 842132-96-1P 842132-97-2P 842132-98-3P
 842132-99-4P 842133-00-0P 842133-55-5P
 842133-56-6P 842134-30-9P 842134-45-6P
 842134-54-7P 842134-55-8P 842134-83-2P
 842134-98-9P 842134-99-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)

RN 761423-35-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-36-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-38-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(3-methylbenzo[b]thien-2-yl)methyl]phenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-80-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-fluorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-81-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-83-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxyphenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-86-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-87-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-
, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 842132-57-4 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-, (1S)-, compd. with benzo[b]thiophene (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 761424-02-6
 CMF C21 H22 O5 S

Absolute stereochemistry.




CM 2

CRN 95-15-8
 CMF C8 H6 S



RN 842132-72-3 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-73-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-ethoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-74-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxy-1-naphthalenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-75-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(trifluoromethyl)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-76-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-77-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-78-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-79-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-80-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-81-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5,7-dimethylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-82-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-83-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-84-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-85-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(trifluoromethyl)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-86-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-87-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-fluoro-3-[(6-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-88-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-chlorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-89-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-90-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-91-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-92-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-fluoro-6-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-93-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-94-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(7-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-95-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-96-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-fluoro-3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-97-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chlorobenzo[b]thien-2-yl)methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-98-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842132-99-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-ethylphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-00-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-(trifluoromethylphenyl)]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-55-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1-oxidobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842133-56-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1,1-dioxidobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-30-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(1-methylethyl)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-45-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-ethylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-54-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-propoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-55-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(2-fluoroethoxy)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-83-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[5-ethoxybenzo[b]thien-2-yl]methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-98-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[6-(difluoromethoxy)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842134-99-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[6-(difluoromethoxy)benzo[b]thien-2-yl]methyl]-4-methylphenyl]-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 842132-54-1P 842132-56-3P 842133-53-3P

842133-54-4P 842136-98-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)

RN 842132-54-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylhydroxymethyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 842132-56-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-, compd. with benzo[b]thiophene (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 761422-37-1
CMF C49 H46 O5 S

Absolute stereochemistry.




CM 2

CRN 95-15-8
CMF C8 H6 S




RN 842133-53-3 CAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-
, tetraacetate, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 842133-54-4 CAPLUS
CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(1-oxidobenzo[b]thien-2-yl)methyl]phenyl]-, tetraacetate, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842136-98-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(6-ethoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 24 Sep 2004

ACCESSION NUMBER: 2004:780686 CAPLUS

DOCUMENT NUMBER: 141:296242

TITLE: Preparation of C-glycoside derivatives and salts thereof as Na⁺-glucose co-transporter inhibitor

INVENTOR(S): Imamura, Masakazu; Murakami, Takeshi; Shiraki, Ryota; Ikegai, Kazuhiro; Sugane, Takashi; Iwasaki, Fumiyoshi; Kurosaki, Eiji; Tomiyama, Hiroshi; Noda, Atsushi; Kitta, Kayoko; Kobayashi, Yoshinori

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co. Ltd., Japan; Kotobuki Pharmaceutical Co. Ltd.

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080990	A1	20040923	WO 2004-JP3324	20040312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				


BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004220222	A1	20040923	AU 2004-220222	20040312
CA 2526145	AA	20040923	CA 2004-2526145	20040312
EP 1609785	A1	20051228	EP 2004-720254	20040312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008140	A	20060301	BR 2004-8140	20040312
CN 1802366	A	20060712	CN 2004-80006761	20040312
US 2006122126	A1	20060608	US 2005-541615	20050707
NO 2005004713	A	20051214	NO 2005-4713	20051013
PRIORITY APPLN. INFO.:			JP 2003-70297	A 20030314
			WO 2004-JP3324	A 20040312

OTHER SOURCE(S): MARPAT 141:296242
GI



I



II

AB C-glycoside derivs. represented by the following general formula (I) or salts thereof [wherein ring A = benzene, 5- or 6-membered monocyclic heteroaryl ring containing 1-4 heteroatoms selected from N, S, and O, or (un)saturated 8- to 10-membered bicyclic heterocyclic ring containing 1-4 heteroatoms selected from N, S, and O; ring B = (un)saturated 8- to 10-membered bicyclic heterocyclic ring containing 1-4 heteroatoms selected from N, S, and O, (un)saturated 5- to 6-membered heterocyclic ring containing

1-4

heteroatoms selected from N, S, and O, (un)saturated 8- to 10-membered carbocyclic ring, or benzene ring; X = a bond, lower alkylene; R1-R4 = H, lower alkyl, lower alkylcarbonyl, lower alkylene-aryl; R5=R11 = H, lower alkyl, cycloalkyl, halo, halo-lower alkyl, OH, oxo, NH2, lower alkylsulfonyl, halo-lower alkylsulfonyl, arylsulfonyl, aryl, (un)saturated 5- or 6-membered monocyclic heterocyclyl containing 1-4 heteroatoms selected from N, S, and O, hydroxy-lower alkyl, lower alkoxy-lower alkyl, etc.] are prepared These C-glycosides, more specifically C-glucosides, are useful as Na⁺-glucose cotransporter inhibitors in remedies for, e.g., diabetes, in particular, insulin-independent diabetes (type 2 diabetes) and insulin-dependent diabetes (type 1 diabetes), as well as remedies for insulin resistance diseases and various diseases relating to diabetes including obesity. Thus, lithiation of benzo[b]thiophene with BuLi/hexane in THF at -78° for 2 h, addition reaction with 3-(2,3,4,6-tetra-O-

benzyl- β -D-glucopyranosyl)benzaldehyde for 5 h, reduction with triethylsilane in the presence of BF₃.OEt₂ in CH₂Cl₂ for 2 h under ice-cooling, and finally debenzylation with BBr₃/heptane in CH₂Cl₂ at -78° for 90 min gave (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[3-(1-benzothiophen-2-ylmethyl)phenyl]-D-glucitol (II; R = H). II (R = OMe) showed IC₅₀ of 3.8 nM for inhibiting the uptake of Me α -D-(U-14C)glucopyranoside in CHO cells stably expressing human Na⁺-glucose transporter (SGLT2).

IT 761423-35-2P 761423-36-3P 761423-37-4P
 761423-38-5P 761423-39-6P 761423-40-9P
 761423-41-0P 761423-42-1P 761423-43-2P
 761423-44-3P 761423-51-2P 761423-52-3P
 761423-54-5P 761423-56-7P 761423-58-9P
 761423-60-3P 761423-62-5P 761423-64-7P
 761423-66-9P 761423-69-2P 761423-71-6P
 761423-74-9P 761423-77-2P 761423-78-3P
 761423-79-4P 761423-80-7P 761423-81-8P
 761423-82-9P 761423-83-0P 761423-84-1P
 761423-85-2P 761423-86-3P 761423-87-4P
 761423-88-5P 761423-89-6P 761423-90-9P
 761423-91-0P 761423-92-1P 761423-93-2P
 761423-94-3P 761423-95-4P 761424-02-6P
 761424-06-0P 761424-07-1P 761424-08-2P
 761424-09-3P 761424-29-7P 761424-30-0P
 761424-31-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of C-glycoside derivs. and salts thereof as Na⁺-glucose cotransporter inhibitors for treatment of diabetes)

RN 761423-35-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-36-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-37-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chlorobenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-38-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(3-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-39-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluoro-3-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-40-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chloro-3-methylbenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-41-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(1,1-dimethylethyl)benzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-42-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-43-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(dimethylamino)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-44-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(diethylamino)benzo[b]thien-2-yl]methyl]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-51-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-hydroxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-52-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-methoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-54-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(2-methoxyethoxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-56-7 CAPLUS

CN Acetamide, N-[2-[4-(benzo[b]thien-2-ylmethyl)-2-β-D-glucopyranosylphenoxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-58-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[2-(methylamino)ethoxy]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-60-3 CAPLUS

CN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-2-beta-D-glucopyranosylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 761423-62-5 CAPLUS

CN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-2-beta-D-

glucopyranosylphenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-64-7 CAPLUS

CN Acetamide, 2-[4-(benzo[b]thien-2-ylmethyl)-2-β-D-glucopyranosylphenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-66-9 CAPLUS

CN Acetamide, 2-[4-(benzo[b]thien-2-ylmethyl)-2-β-D-glucopyranosylphenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-69-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(2-hydroxyethoxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-71-6 CAPLUS

CN D-Glucitol, 1-C-[2-amino-5-(benzo[b]thien-2-ylmethyl)phenyl]-1,5-anhydro-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-74-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(methylamino)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-77-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[(2-hydroxyethyl)amino]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-78-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(dimethylamino)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-79-4 CAPLUS


CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(4-morpholinyl)phenyl]-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.,




RN 761423-80-7 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-fluorophenyl]-
 , (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 761423-81-8 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-
 , (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 761423-82-9 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-hydroxyphenyl]-
 , (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-83-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-84-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-(2-hydroxyethoxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-85-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-[2-(dimethylamino)ethoxy]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-86-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-87-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-88-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-fluorophenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-89-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[2-(benzo[b]thien-2-ylmethyl) [1,1'-biphenyl]-4-yl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-90-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2,4-dimethoxyphenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-91-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2,4-dihydroxyphenyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-92-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-fluoro-2-hydroxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-93-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-hydroxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-94-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-methoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-95-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-(2-hydroxyethoxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-02-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-06-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(cyclopentyloxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-07-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(1-methylethoxy)phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-08-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[(2R)-2,3-dihydroxypropoxy]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-09-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-fluoro-2-methoxyphenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-29-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[2-(dimethylamino)ethoxy]phenyl]-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-30-0 CAPLUS

CN Benzoic acid, 4-(benzo[b]thien-2-ylmethyl)-2-β-D-glucopyranosyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761424-31-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(hydroxymethyl)phenyl]-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 761422-37-1P 761422-38-2P 761422-39-3P
 761422-40-6P 761422-41-7P 761422-42-8P
 761422-43-9P 761422-44-0P 761422-45-1P
 761422-46-2P 761422-47-3P 761422-48-4P
 761422-49-5P 761422-50-8P 761422-51-9P
 761422-58-6P 761422-61-1P 761422-62-2P
 761422-63-3P 761422-64-4P 761422-66-6P
 761422-67-7P 761422-68-8P 761422-69-9P
 761422-70-2P 761422-71-3P 761422-72-4P
 761422-73-5P 761422-74-6P 761422-75-7P
 761422-76-8P 761422-77-9P 761422-78-0P
 761422-79-1P 761422-80-4P 761422-81-5P
 761422-82-6P 761422-83-7P 761422-84-8P
 761422-85-9P 761422-86-0P 761422-87-1P
 761422-88-2P 761422-89-3P 761422-90-6P
 761422-91-7P 761422-92-8P 761422-93-9P
 761422-94-0P 761422-95-1P 761422-96-2P
 761422-97-3P 761422-98-4P 761422-99-5P
 761423-00-1P 761423-01-2P 761423-02-3P
 761423-03-4P 761423-04-5P 761423-05-6P
 761425-10-9P 761425-13-2P 761425-14-3P
 761425-16-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of C-glycoside derivs. and salts thereof as Na⁺-glucose cotransporter inhibitors for treatment of diabetes)

RN 761422-37-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-38-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methylbenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-39-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chlorobenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-40-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluorobenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-41-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-fluoro-3-methylbenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-42-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-chloro-3-methylbenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-43-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(1,1-dimethylethyl)benzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-44-0 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(5-methoxybenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-45-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(dimethylamino)benzo[b]thien-2-yl]methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-46-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(diethylamino)benzo[b]thien-2-yl]methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-47-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(4-morpholinyl)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-48-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-5-fluorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-49-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-chlorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-50-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-51-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-fluoro-2-(phenylmethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 761422-58-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-[(3-methylbenzo[b]thien-2-yl)methyl]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-61-1 CAPLUS


CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 761422-62-2 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2,4-bis(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 761422-63-3 CAPLUS
 CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-methoxy-2-(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-64-4 CAPLUS

RN D-Glucitol, 1,5-anhydro-1-C-[2-(benzo[b]thien-2-ylmethyl)[1,1'-biphenyl]-4-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-66-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-hydroxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-67-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-hydroxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-68-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-hydroxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-69-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-methoxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-70-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-methoxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-71-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(2-methoxyethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-72-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-(2-hydroxyethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-73-5 CAPLUS


CN Carbamic acid, [2-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 761422-74-6 CAPLUS
CN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 761422-75-7 CAPLUS
CN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-5-chloro-2-[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 761422-76-8 CAPLUS
CN Glycine, N-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-77-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[2-(methylamino)ethoxy]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-78-0 CAPLUS

CN Acetamide, N-[2-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-79-1 CAPLUS

CN D-Glucitol, 1-C-[2-(acetyloxy)-5-(benzo[b]thien-2-ylmethyl)phenyl]-1,5-anhydro-, tetraacetate, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-80-4 CAPLUS

CN D-Glucitol, 1-C-[2-(acetyloxy)-5-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-1,5-anhydro-, tetraacetate, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-81-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-hydroxyphenyl]-, 2,3,4,6-tetraacetate, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-82-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-fluoro-2-hydroxyphenyl]-, 2,3,4,6-tetraacetate, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-83-7 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(cyclopentyloxy)phenyl]-, tetraacetate, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-84-8 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-fluoro-2-methoxyphenyl]-, tetraacetate, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-85-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(1-methylethoxy)phenyl]-, tetraacetate, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-86-0. CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[[4R]-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-, tetraacetate, (1S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 761422-87-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[[[trifluoromethyl]sulfonyl]oxy]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-88-2 CAPLUS

CN Benzoic acid, 4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-89-3 CAPLUS

CN Benzoic acid, 4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-90-6 CAPLUS

CN Acetic acid, [4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-91-7 CAPLUS

CN Acetamide, 2-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-92-8 CAPLUS

CN Acetamide, 2-[4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-93-9 CAPLUS

CN Carbamic acid, [4-(benzo[b]thien-2-ylmethyl)-2-[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-94-0 CAPLUS

CN D-Glucitol, 1-C-[2-amino-5-(benzo[b]thien-2-ylmethyl)phenyl]-1,5-anhydro-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-95-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(methylamino)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-96-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-[(2-hydroxyethyl)amino]phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-97-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(2-hydroxyethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761422-98-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-4-chloro-2-(2-hydroxyethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 761422-99-5 CAPLUS

CN D-Glucitol, 1-C-[2-(2-aminoethoxy)-5-(benzo[b]thien-2-ylmethyl)phenyl]-1,5-

anhydro-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-00-1 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(dimethylamino)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 761423-01-2 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-02-3 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-chlorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-03-4 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-fluorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-04-5 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761423-05-6 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-, (1S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761425-10-9 CAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[5-(benzo[b]thien-2-ylmethyl)-2-(methoxymethoxy)phenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761425-13-2 CAPLUS

CN α -D-Glucopyranose, 1-C-[3-[benzo[b]thien-2-yl][(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-4-fluorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761425-14-3 CAPLUS

CN α -D-Glucopyranose, 1-C-[3-(benzo[b]thien-2-ylhydroxymethyl)-4-fluorophenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 761425-16-5 CAPLUS

CN α-D-Glucopyranose, 1-C-[3-(benzo[b]thien-2-ylmethyl)-4-methoxyphenyl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:36:59 ON 15 NOV 2006)

FILE 'REGISTRY' ENTERED AT 15:38:40 ON 15 NOV 2006

L1 STRUCTURE UPLOADED

L2 11 S L1 SSS SAM

L3 182 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:41:23 ON 15 NOV 2006

L4 4 S L3